Skip to main content
SpringerLink
Log in

Orale Kontrazeption und das Risiko gynäkologischer Tumoren

Oral contraceptives and the risk of gynecologic cancer

  • Leitthema
  • Published:
Der Gynäkologe Aims and scope

Zusammenfassung

Sexualhormone können Einfluss auf die Entwicklung von Tumoren haben. Randomisierte, kontrollierte Studien aus dem Bereich der Hormontherapie postmenopausaler Frauen zeigen, dass synthetische Sexualsteroide das Risiko für gynäkologische Tumoren erhöhen können. Für kombinierte orale Kontrazeptiva, die zweite große Gruppe synthetischer Sexualsteroide, liegen ebenfalls Studienergebnisse vor, die einen Zusammenhang zwischen deren Einnahme und gynäkologischen Tumoren zeigen. Der Beitrag gibt einen Überblick über die aktuelle Datenlage, dabei werden neben den malignen auch benigne Tumoren berücksichtigt.

Abstract

Sexual steroids can influence the development of certain cancers. Randomized controlled trials in the field of hormonal therapy in postmenopausal women showed an increased risk for gynecologic cancers during the intake of synthetic sex steroids. Research on the use of combined oral contraceptives (COC)—the second largest group of synthetic sex steroids—also showed an effect on cancer risk. This report provides an overview of the current evidence concerning the influence of COC on the development of gynecologic malignant/benign tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) (2008) Empfängnisverhütung, Leitlinie der DGGG

  2. Anderson GL et al (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA 290(13):1739–1748

    Article  CAS  PubMed  Google Scholar 

  3. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) (2009) Hormontherapie in der Peri- und Postmenopause (HT), Leitlinie der DGGG

  4. Tan-Chiu E et al (2003) Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst 95(4): 302–307

    Article  CAS  PubMed  Google Scholar 

  5. Rohan TE, Miller AB (1999) Hormone replacement therapy and risk of benign proliferative epithelial disorders of the breast. Eur J Cancer Prev 8(2):123–130

    Article  CAS  PubMed  Google Scholar 

  6. Rohan TE, Miller AB (1999) A cohort study of oral contraceptive use and risk of benign breast disease. Int J Cancer 82(2):191–196

    Article  CAS  PubMed  Google Scholar 

  7. Vessey M, Yeates D (2007) Oral contraceptives and benign breast disease: an update of findings in a large cohort study. Contraception 76(6):418–424

    Article  CAS  PubMed  Google Scholar 

  8. Claus EB, Stowe M, Carter D (2003) Oral contraceptives and the risk of ductal breast carcinoma in situ. Breast Cancer Res Treat 81(2):129–136

    Article  CAS  PubMed  Google Scholar 

  9. Leidenberger S, Ortmann O (2009) Klinische Endokrinologie für Frauenärzte, 3. Aufl. Springer, Berlin Heidelberg New York Tokio

  10. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347(9017):1713–1727

    Article  Google Scholar 

  11. IARC (1997) Hormonal contraception and post-menopausal hormonal therapy. IARC Monographs on The Evaluation of Carcinogenic Risks to Humans

  12. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2007) Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. IARC Monogr Eval Carcinog Risks Hum 91:1–528

    Google Scholar 

  13. Kahlenborn C et al (2006) Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc 81(10):1290–1302

    Article  PubMed  Google Scholar 

  14. Russo J et al (2005) The protective role of pregnancy in breast cancer. Breast Cancer Res 7(3):131–142

    Article  PubMed  Google Scholar 

  15. Marchbanks PA et al (2002) Oral contraceptives and the risk of breast cancer. N Engl J Med 346(26):2025–2032

    Article  CAS  PubMed  Google Scholar 

  16. Vessey M, Painter R (2006) Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004. Br J Cancer 95(3):385–389

    Article  CAS  PubMed  Google Scholar 

  17. Milne RL et al (2005) Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 14(2):350–356

    Article  CAS  PubMed  Google Scholar 

  18. Heimdal K, Skovlund E, Moller P (2002) Oral contraceptives and risk of familial breast cancer. Cancer Detect Prev 26(1):23–27

    Article  CAS  PubMed  Google Scholar 

  19. Figueiredo JC et al (2010) Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study. Breast Cancer Res Treat 120(1):175–183

    Article  CAS  PubMed  Google Scholar 

  20. Brohet RM et al (2007) Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 25(25):3831–3836

    Article  PubMed  Google Scholar 

  21. Flake GP, Andersen J, Dixon D (2003) Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 111(8):1037–1054

    Article  CAS  PubMed  Google Scholar 

  22. Brandon DD et al (1993) Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 169(1):78–85

    CAS  PubMed  Google Scholar 

  23. Parazzini F et al (1992) Oral contraceptive use and risk of uterine fibroids. Obstet Gynecol 79(3):430–433

    Article  CAS  PubMed  Google Scholar 

  24. Ratech H, Stewart ME (1982) Uterine leiomyomas, serum cholesterol, and oral contraceptives. A preliminary study of epidemiologic differences in Los Angeles, California and Albany, New York. Diagn Gynecol Obstet 4(1):21–24

    CAS  PubMed  Google Scholar 

  25. Ross RK et al (1986) Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed) 293(6543):359–362

    Article  Google Scholar 

  26. Weiss NS, Szekely DR, Austin DF (1976) Increasing incidence of endometrial cancer in the United States. N Engl J Med 294(23):1259–1262

    Article  CAS  PubMed  Google Scholar 

  27. Cohen I (2004) Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 94(2):256–266

    Article  CAS  PubMed  Google Scholar 

  28. Cust AE et al (2007) Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 14(3):755–767

    Article  CAS  PubMed  Google Scholar 

  29. Reeves GK et al (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335(7630):1134

    Article  PubMed  Google Scholar 

  30. Hannaford PC et al (2007) Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ 335(7621):651

    Article  PubMed  Google Scholar 

  31. Maxwell GL et al (2006) Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol 103(2):535–540

    Article  CAS  PubMed  Google Scholar 

  32. Weiderpass E et al (1999) Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 10(4):277–284

    Article  CAS  PubMed  Google Scholar 

  33. Schlesselman JJ (1997) Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner’s guide to meta-analysis. Hum Reprod 12(9):1851–1863

    Article  CAS  PubMed  Google Scholar 

  34. Vessey M et al (1987) Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. Br Med J (Clin Res Ed) 294(6586):1518–1520

    Article  Google Scholar 

  35. (n a) (2009) Cochrane Update. Oral contraceptives for functional ovarian cysts. Obstet Gynecol 114(3):679–680

  36. Leitzmann MF et al (2009) Body mass index and risk of ovarian cancer. Cancer 115(4):812–822

    Article  PubMed  Google Scholar 

  37. Beral V et al (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371(9609):303–314

    Article  CAS  PubMed  Google Scholar 

  38. Lurie G et al (2008) Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology 19(2):237–243

    Article  PubMed  Google Scholar 

  39. Moorman PG et al (2008) Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol 167(9):1059–1069

    Article  PubMed  Google Scholar 

  40. Royar J, Becher H, Chang-Claude J (2001) Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 95(6):370–374

    Article  CAS  PubMed  Google Scholar 

  41. McLaughlin JR et al (2007) Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 8(1):26–34

    Article  CAS  PubMed  Google Scholar 

  42. Narisawa-Saito M, Kiyono T (2007) Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci 98(10):1505–1511

    Article  CAS  PubMed  Google Scholar 

  43. Moodley M et al (2003) The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. Int J Gynecol Cancer 13(2):103–110

    Article  CAS  PubMed  Google Scholar 

  44. Smith JS et al (2003) Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361(9364):1159–1167

    Article  PubMed  Google Scholar 

  45. Appleby P et al (2007) Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370(9599):1609–1621

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Frauenheilkunde und Geburtshilfe am Caritas-Krankenhaus St. Josef, Universität Regensburg, Landshuter Str. 65, 93053, Regensburg, Deutschland

    M. Ponnath &  O. Ortmann

Authors
  1. M. Ponnath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Ortmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. Ortmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ponnath, M., Ortmann, O. Orale Kontrazeption und das Risiko gynäkologischer Tumoren. Gynäkologe 44, 37–42 (2011). https://doi.org/10.1007/s00129-010-2665-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-010-2665-7

Schlüsselwörter

Keywords

Search

Navigation